KIORA PHARMACEUTICALS INC (KPRX): Nasdaq/NYSE listing notice — Kiora Pharmaceuticals receives Nasdaq extension to July 15, 2024 for bid price compliance

KIORA PHARMACEUTICALS INC

Nasdaq grants additional 180-day compliance period until July 15, 2024 for $1.00 minimum bid price rule.
Company failed to regain compliance by original deadline of January 15, 2024; stock below $1 since July 2023.
Extension conditioned on meeting market value of publicly held shares and other initial listing standards.
Company evaluating reverse stock split to cure deficiency; no assurance of regaining compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

KIORA PHARMACEUTICALS INC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

January 16, 2024, Nasdaq notified the Company in writing (the “Extension Letter”) that while the Company had not regained compliance with the Bid Price Rule, it was eligible for an additional 180-day compliance period, or until July 15, 2024, to regain compliance with the Bid Price Rule. Nasdaq’s determination was based on the Company having met the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market, with the exception of the Bid Price Rule, and on the Company’s written notice to Nasdaq o

View on SEC.gov

Browse all listing & compliance notices →

KIORA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001372514-24-000002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.